Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment ...
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1, a self-developed and ...
Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication ...
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price in January. But this ...
Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good morning and welcome to Summit Therapeutics Fourth Quarter and Year End 2024 Earnings and Update Call. All participants will be in ...
The American Heart Association says nearly half of all adults in the U.S. have some form of cardiovascular disease. We've all heard a poor diet, lack of exercise and smoking can lead to it, but ...
Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Several Asia biotechs this week – including Innocare Pharma Ltd., Akeso Pharmaceuticals Inc., Sanbio Co. Ltd. and Ascletis Pharma Inc. – unveiled the start of new late-stage clinical trials or interim ...
A paper published in The Lancet showed that four out of four young children with Leber congenital amaurosis 4 retinal dystrophy due to a genetic deficiency of Aryl-hydrocarbon-interacting protein-like ...
In recent months China’s progress in artificial intelligence has stunned the world. A quieter yet equally significant shift ...